Mitsubishi Tanabe Pharma Corporation

Overview

Mitsubishi Tanabe Pharma Corporation is a pharmaceutical company based in Japan. It is engaged in the research, development, manufacture, and sale of pharmaceutical products, focusing on novel and unique pharmaceuticals for specialized fields like cardiovascular and central nervous system diseases.

Therapeutic areas

API / Drug Master Files

Mitsubishi Tanabe Pharma Corporation holds 0 active (11 total) FDA Type II Drug Master Files — identifying it as an active-substance / API supplier. Type II DMFs are filed with the FDA to support the use of an active pharmaceutical ingredient in drug applications.

• MT-7716 DRUG SUBSTANCEInactive2009-12-21
• MP-124 DRUG SUBSTANCEInactive2006-06-28
• Y-39983 DRUG SUBSTANCEInactive2006-05-22
• MP-513 DRUG SUBSTANCEInactive2005-09-09
• MCC-257Inactive2002-07-30
• MCI-196 DRUG SUBSTANCEInactive2002-04-22
• MKC-242 BULK DRUG SUBSTANCEInactive1999-06-29
• MCC-555Inactive1999-02-17
• MCC-135 (BULK DRUG SUBSTANCE)Inactive1998-07-15
• DILTIAZEM HYDROCHLORIDE (PROCESS C)Inactive1993-07-09
• MCI-9038 ARGATROBAN DRUG SUB.Inactive1988-12-08

FDA compliance signals

No FDA recalls, Warning Letters, or Form 483 observations are linked to Mitsubishi Tanabe Pharma Corporation in our records. PharmaTek screens the full directory against live FDA enforcement data.